Imagine trying to protect a mother and baby from a parasite that specifically attacks the placenta. This work creates a better 'shield' by combining two different vaccine versions or using tiny virus-like particles to make the immune system react more strongly. It also builds a digital system to track pregnancies and health outcomes via mobile apps to ensure the medicine works in the real world.
Placental malaria causes massive mortality in pregnant women and infants, but existing vaccine candidates lack the cross-reactivity needed for large-scale phase II trials. There is also a lack of digital infrastructure to track pregnancy outcomes in endemic regions.
Optimized GMP manufacturing processes for two vaccine candidates and mobile applications for pregnancy outcome tracking.
If you are a vaccine manufacturer dealing with low cross-reactivity in malaria candidates — this project developed a co-administration approach using PRIMVAC and PAMVAC-cVLP that increases antibody titers. This allows for a more effective product before moving into expensive phase II trials.
If you are a digital health company dealing with poor patient tracking in remote regions — this project developed mobile applications for tracking pregnancy outcomes. This provides a validated model for monitoring vaccine efficacy in endemic regions.
If you are a CMO dealing with the need for specialized GMP vaccine production — this project developed optimized manufacturing processes for PAMVAC-cVLP. This creates a blueprint for scaling the production of virus-like particle vaccines.
The project received an EU contribution of EUR 9,999,995.
The manufacturing process for PAMVAC-cVLP has been optimized and is ready for transfer to the CMO, though GMP batch release for PRIMVAC is expected between Q4 2024 and January 2025.
Based on available project data, specific licensing terms are not mentioned, but the project focuses on optimizing vaccine candidates PRIMVAC and PAMVAC-cVLP for future clinical trials.
The project period runs from 2022-06-01 to 2027-05-31, with specific GMP batch releases expected by January 2025.
Effectiveness is measured by antibody levels and cross-inhibitory titers, supported by cost-effectiveness modeling and digital pregnancy registers.
The consortium is well-balanced for a clinical transition project, consisting of 10 partners across 8 countries. With a 20% industry ratio (2 companies) and a strong mix of 4 research institutes and 3 universities, the group combines academic discovery with the manufacturing capability needed to move from lab to GMP production.
Contact the European Vaccine Initiative EV in Germany
Contact us to explore licensing opportunities for the PAMVAC-cVLP manufacturing process.
